Skip to Main Content

CHICAGO — When cancer drugs granted accelerated approval in the U.S. later turn out not to benefit patients, the Food and Drug Administration would prefer drugmakers remove them from the market voluntarily. But very few companies are willing to do that, which sometimes forces Richard Pazdur, the agency’s top cancer drug regulator, to pick up the phone and have a blunt conversation with drug company executives.

“Peggy Hamburg, a former FDA commissioner, gave me a phrase that I often use — if you don’t see the light, you will soon feel the heat,” Pazdur said Friday evening, speaking at a STAT event during the annual meeting of the American Society of Clinical Oncology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment